Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.

Murphy MG, Bach MA, Plotkin D, Bolognese J, Ng J, Krupa D, Cerchio K, Gertz BJ

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Jul 1999Cited by 29 (Europe PMC)

PMID10404019DOI10.1359/jbmr.1999.14.7.1182PepBankPUB-10404019

Source link PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In functionally impaired elderly subjects, pooled MK‑677 groups increased mean serum osteocalcin by 29.4% versus placebo.
In plain wordsIn functionally impaired elderly adults, MK‑677 increased osteocalcin more than placebo.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseSerum osteocalcin in functionally impaired subjects
Study
n = 91
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5, 10, or 25 mg daily for 2 weeks followed by 25 mg daily for 7 weeks · oral · 9 weeksAs given in this study (human).
Measurements
Osteocalcin increase
29.4%
pooled MK-677 groups
P value for Mean serum osteocalcin, all MK-677 groups combined versus placebo at 9 weeks in functionally impaired subjects
< 0.001 p value
Mean serum osteocalcin, all MK-677 groups combined versus placebo at 9 weeks in functionally impaired subjects
Source sentences
Summary
Treatment with MK-677 (all MK-677 groups combined) for 9 weeks increased mean serum osteocalcin by 29.4% and BSAP by 10.4% (p < 0.001 vs. placebo) and mean urinary NTX excretion by 22.6% (p < 0.05 vs. placebo).
2 context sentences(design, population, supporting numbers)
Summary · context
Subsequently, the biological effects of MK-677 were studied in 105 elderly subjects who met objective criteria for functional impairment.
Summary · context
Subjects were randomized to receive oral doses of placebo for 9 weeks or either 5, 10, or 25 mg of MK-677 daily for an initial 2 weeks followed by 25 mg of MK-677 daily for the next 7 weeks(n = 63 on MK-677 and n = 28 on placebo completed 9 weeks of therapy).
Report a problemFND-1040401905
02HumanRandomized controlled trialEfficacy outcome
In functionally impaired elderly subjects, pooled MK‑677 groups increased mean serum BSAP by 10.4% versus placebo.
In plain wordsIn functionally impaired elderly adults, MK‑677 increased the bone formation marker BSAP more than placebo.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseBSAP in functionally impaired subjects
Study
n = 91
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5, 10, or 25 mg daily for 2 weeks followed by 25 mg daily for 7 weeks · oral · 9 weeksAs given in this study (human).
Measurements
BSAP increase
10.4%
pooled MK-677 groups
P value for Mean serum BSAP, all MK-677 groups combined versus placebo at 9 weeks in functionally impaired subjects
< 0.001 p value
Mean serum BSAP, all MK-677 groups combined versus placebo at 9 weeks in functionally impaired subjects
Source sentences
Summary
Treatment with MK-677 (all MK-677 groups combined) for 9 weeks increased mean serum osteocalcin by 29.4% and BSAP by 10.4% (p < 0.001 vs. placebo) and mean urinary NTX excretion by 22.6% (p < 0.05 vs. placebo).
2 context sentences(design, population, supporting numbers)
Summary · context
Subsequently, the biological effects of MK-677 were studied in 105 elderly subjects who met objective criteria for functional impairment.
Summary · context
Subjects were randomized to receive oral doses of placebo for 9 weeks or either 5, 10, or 25 mg of MK-677 daily for an initial 2 weeks followed by 25 mg of MK-677 daily for the next 7 weeks(n = 63 on MK-677 and n = 28 on placebo completed 9 weeks of therapy).
Report a problemFND-1040401906
03HumanRandomized controlled trialEfficacy outcome
In functionally impaired elderly subjects, pooled MK‑677 groups increased mean urinary NTX excretion by 22.6% versus placebo.
In plain wordsIn functionally impaired elderly adults, MK‑677 increased the bone resorption marker more than placebo.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseUrinary NTX in functionally impaired subjects
Study
n = 91
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5, 10, or 25 mg daily for 2 weeks followed by 25 mg daily for 7 weeks · oral · 9 weeksAs given in this study (human).
Measurements
Urinary NTX increase
22.6%
pooled MK-677 groups
P value for Mean urinary NTX excretion, all MK-677 groups combined versus placebo at 9 weeks in functionally impaired subjects
< 0.05 p value
Mean urinary NTX excretion, all MK-677 groups combined versus placebo at 9 weeks in functionally impaired subjects
Source sentences
Summary
Treatment with MK-677 (all MK-677 groups combined) for 9 weeks increased mean serum osteocalcin by 29.4% and BSAP by 10.4% (p < 0.001 vs. placebo) and mean urinary NTX excretion by 22.6% (p < 0.05 vs. placebo).
2 context sentences(design, population, supporting numbers)
Summary · context
Subsequently, the biological effects of MK-677 were studied in 105 elderly subjects who met objective criteria for functional impairment.
Summary · context
Subjects were randomized to receive oral doses of placebo for 9 weeks or either 5, 10, or 25 mg of MK-677 daily for an initial 2 weeks followed by 25 mg of MK-677 daily for the next 7 weeks(n = 63 on MK-677 and n = 28 on placebo completed 9 weeks of therapy).
Report a problemFND-1040401907
04HumanRandomized controlled trialMechanism
In the MK‑677 group of functionally impaired elderly subjects, osteocalcin change correlated positively with IGF-I change.
In plain wordsIn elderly adults receiving MK‑677, changes in osteocalcin and IGF-I were positively linked.
Peptide
MK-677 (ibutamoren)
Outcome
Not applicableOsteocalcin and IGF-I change correlation
Study
n = 63
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5, 10, or 25 mg daily for 2 weeks followed by 25 mg daily for 7 weeks · oral · 9 weeksAs given in this study (human).
Measurements
Correlation coefficient
0.37 r
osteocalcin versus IGF-I change
P value for Correlation of change from baseline serum osteocalcin with change from baseline serum IGF-I in the MK-677 group
< 0.01 p value
Correlation of change from baseline serum osteocalcin with change from baseline serum IGF-I in the MK-677 group
Source sentences
Summary
The change from baseline serum osteocalcin correlated with the change from baseline serum IGF-I in the MK-677 group (r = 0.37; p < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
Subsequently, the biological effects of MK-677 were studied in 105 elderly subjects who met objective criteria for functional impairment.
Summary · context
Subjects were randomized to receive oral doses of placebo for 9 weeks or either 5, 10, or 25 mg of MK-677 daily for an initial 2 weeks followed by 25 mg of MK-677 daily for the next 7 weeks(n = 63 on MK-677 and n = 28 on placebo completed 9 weeks of therapy).
Report a problemFND-1040401908
05HumanRandomized controlled trialEfficacy outcome
In healthy elderly subjects, MK‑677 increased mean serum osteocalcin by 8% versus placebo.
In plain wordsIn healthy elderly adults, MK‑677 increased the bone formation marker osteocalcin more than placebo.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseSerum osteocalcin in healthy elderly subjects
Study
n = 50
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
25 mg daily for 2 weeks followed by 50 mg daily for 2 weeks · oral · 4 weeksAs given in this study (human).
Measurements
Osteocalcin increase
8%
MK-677
P value for Mean serum osteocalcin, MK-677 versus placebo in the 4-week healthy elderly study
< 0.05 p value
Mean serum osteocalcin, MK-677 versus placebo in the 4-week healthy elderly study
Source sentences
Summary
MK-677 increased mean serum osteocalcin by 8% (p < 0.05 vs. placebo).
1 context sentence(design, population, supporting numbers)
Summary · context
Additionally, 50 healthy elderly subjects received either placebo (n = 20) for 4 weeks or 25 mg of MK-677 (n = 30) daily for 2 weeks followed by 50 mg daily for 2 weeks.
Report a problemFND-1040401903
06HumanRandomized controlled trialEfficacy outcome
In healthy elderly subjects, MK‑677 10 mg increased mean urine NTX by 10% versus placebo.
In plain wordsIn healthy elderly adults, MK‑677 10 mg increased the bone resorption marker more than placebo.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseUrine NTX with 10 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
10 mg · oral · 2 weeksAs given in this study (human).
Measurements
Urine NTX increase
10%
10 mg
P value for Mean urine NTX, MK-677 10 mg versus placebo at 2 weeks
< 0.05 p value
Mean urine NTX, MK-677 10 mg versus placebo at 2 weeks
Source sentences
Summary
Treatment with 10 mg and 25 mg of MK-677 for 2 weeks increased mean urine NTXs 10% and 17%, respectively (p < 0.05 vs. placebo).
1 context sentence(design, population, supporting numbers)
Summary · context
Dose response data were initially obtained in healthy elderly subjects who received oral doses of 10 mg or 25 mg of MK-677 or placebo for 2 weeks (n = 10-12/group).
Report a problemFND-1040401901
07HumanRandomized controlled trialEfficacy outcome
In healthy elderly subjects, MK‑677 25 mg increased mean urine NTX by 17% versus placebo.
In plain wordsIn healthy elderly adults, MK‑677 25 mg increased the bone resorption marker more than placebo.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseUrine NTX with 25 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
25 mg · oral · 2 weeksAs given in this study (human).
Measurements
Urine NTX increase
17%
25 mg
P value for Mean urine NTX, MK-677 25 mg versus placebo at 2 weeks
< 0.05 p value
Mean urine NTX, MK-677 25 mg versus placebo at 2 weeks
Source sentences
Summary
Treatment with 10 mg and 25 mg of MK-677 for 2 weeks increased mean urine NTXs 10% and 17%, respectively (p < 0.05 vs. placebo).
1 context sentence(design, population, supporting numbers)
Summary · context
Dose response data were initially obtained in healthy elderly subjects who received oral doses of 10 mg or 25 mg of MK-677 or placebo for 2 weeks (n = 10-12/group).
Report a problemFND-1040401902
08HumanRandomized controlled trialEfficacy outcome
In both healthy elderly studies, MK‑677 significantly increased serum IGF-I by 55-94%.
In plain wordsIn healthy elderly adults, MK‑677 significantly increased serum IGF-I in both studies.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseSerum IGF-I in healthy elderly studies
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
10 mg or 25 mg for 2 weeks; 25 mg daily for 2 weeks followed by 50 mg daily for 2 weeks · oral · 2 weeks and 4 weeksAs given in this study (human).
Measurements
IGF-I increase
55 to 94%
both studies
Source sentences
Summary
In both studies, MK-677 increased serum IGF-I levels significantly (55-94%).
2 context sentences(design, population, supporting numbers)
Summary · context
Dose response data were initially obtained in healthy elderly subjects who received oral doses of 10 mg or 25 mg of MK-677 or placebo for 2 weeks (n = 10-12/group).
Summary · context
Additionally, 50 healthy elderly subjects received either placebo (n = 20) for 4 weeks or 25 mg of MK-677 (n = 30) daily for 2 weeks followed by 50 mg daily for 2 weeks.
Report a problemFND-1040401904

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.